Pathologic complete response (pCR) to neoadjuvant treatment (NAT) with carboplatin, nab-paclitaxel and anthracycline in early and locally advanced triple-negative breast cancer (TNBC).

被引：0
|
作者：
Miras, Isabel
Gil, Ana
Santos-Fernandez, Paloma
Sanchez-Camacho, Alberto
Falcon Gonzalez, Alejandro
Benavent, Marta
Cejuela Solis, Monica
Bofill, Salvador
Flores, Sandra
Ruiz-Borrego, Manuel
机构：
[1] Univ Hosp Virgen del Rocio, Dept Med Oncol, Seville, Spain
[2] Univ Hosp Puerto Real, Dept Med Oncol, Cadiz, Spain
[3] Univ Hosp Virgen Macarena, Dept Med Oncol, Seville, Spain
[4] Univ Hosp Virgen del Rocio, Seville, Spain
[5] Hosp Virgen del Rocio Sevilla, GEICAM Spanish Breast Canc Grp, Seville, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12608
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pathologic response to neoadjuvant therapy with nab-paclitaxel plus carboplatin followed by anthracycline regimen in triple-negative breast cancer.
    Cardenas, Juan David
    Martinez, Elia
    Alba, Blanca Lourdes Trujillo
    Esteban, Carmen Esteban
    Salvador, Ana Rosa Rubio
    Barahona, Ana Dominguez
    Romero, Cristina
    Sanchez-Simon, Raquel
    Garcia Avila, Maria
    Ignacio Chacon, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with locally advanced triple negative breast cancer
    Yuan, Y.
    Frankel, P.
    Li, M.
    Kruper, L.
    Jones, V.
    Treece, T.
    Waisman, J.
    Yim, J.
    Tumyan, L.
    Schmolze, D.
    Hurria, A.
    Yeon, C.
    Mortimer, J.
    Somlo, G.
    CANCER RESEARCH, 2019, 79 (04)
  • [3] Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer
    Yuan, Yuan
    Lee, Jin Sun
    Yost, Susan E.
    Li, Sierra Min
    Frankel, Paul H.
    Ruel, Christopher
    Schmolze, Daniel
    Robinson, Kim
    Tang, Aileen
    Martinez, Norma
    Stewart, Daphne
    Waisman, James
    Kruper, Laura
    Jones, Veronica
    Menicucci, Andrea
    Uygun, Sahra
    Yoder, Erin
    van der Baan, Bastiaan
    Yim, John H.
    Yeon, Christina
    Somlo, George
    Mortimer, Joanne
    ONCOLOGIST, 2021, 26 (03): : E382 - E393
  • [4] Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
    Altundag, Kadri
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (10): : 986 - 987
  • [5] Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
    Schmid, P.
    Adams, S.
    Rugo, H. S.
    Schneeweiss, A.
    Barrios, C. H.
    Iwata, H.
    Dieras, V.
    Hegg, R.
    Im, S. -A.
    Wright, G. Shaw
    Henschel, V.
    Molinero, L.
    Chui, S. Y.
    Funke, R.
    Husain, A.
    Winer, E. P.
    Loi, S.
    Emens, L. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (22): : 2108 - 2121
  • [6] Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer
    Jiang, Zefei
    Yu, Zhigang
    Geng, Cuizhi
    Lin, Ying
    Liu, Zhenzhen
    Fu, Peifen
    Liu, Qiang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] A phase II trial of neoadjuvant apatinib combined with nab-paclitaxel and carboplatin in triple-negative breast cancer
    Zeng, Tianyu
    Wang, Jue
    Li, Wei
    Sun, Chunxiao
    Yang, Fan
    Liang, Yan
    Fu, Ziyi
    Zha, Xiaoming
    Yin, Yongmei
    ANNALS OF ONCOLOGY, 2022, 33 : S492 - S492
  • [8] Phase II trial of neoadjuvant chemotherapy with carboplatin and nab-paclitaxel in patients with triple negative locally advanced and inflammatory breast cancer
    Somlo, G.
    Chung, S.
    Frankel, P.
    Hurria, A.
    Koehler, S.
    Kruper, L.
    Mortimer, J. E.
    Paz, B.
    Robinson, K.
    Taylor, L.
    Vito, C.
    Waisman, J.
    Yeon, C.
    Yim, J.
    Yuan, Y.
    Tong, T.
    CANCER RESEARCH, 2016, 76
  • [9] Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer REPLY
    Schmid, Peter
    Chui, Stephen Y.
    Emens, Leisha A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (10): : 987 - 988
  • [10] Preferential pathologic complete response (pCR) by triple-negative (-) breast cancer to neoadjuvant docetaxel (T) and carboplatin (C)
    Chang, H. R.
    Slamon, D.
    Gornbein, J. A.
    Chung, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345